News | September 24, 2021
Novavax and Serum seek WHO approval for Covid-19 vaccine
It is a recombinant nanoparticle protein-based vaccine
It is a recombinant nanoparticle protein-based vaccine
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Filing for WHO Emergency Use Authorisation this month
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
The vaccine was 85 percent effective in preventing severe disease across all regions.
Subscribe To Our Newsletter & Stay Updated
